Compare Ascendis Pharma A/S (ASND) vs Devon Energy Corp (DVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Devon Energy Corp — how do they compare? Ascendis Pharma A/S trades at $252.45 (market cap $16.67B), while Devon Energy Corp trades at $45.27 (market cap $49.94B). The key difference: Devon Energy Corp is far larger — about 3× Ascendis Pharma A/S's market cap, and Devon Energy Corp pays a 2.82% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DVN | |
|---|---|---|
Market Cap | $16.67B | $49.94B |
Sector | Health | Energy |
52-Week High | $277.18 | $52.07 |
52-Week Low | $189.74 | $31.74 |
Enterprise Value | $17.04B | $60.68B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Devon Energy (DVN) trades at $45.36, up 5.54% with strong technical momentum and bullish analyst sentiment. The company delivered robust Q2 2026 results, beating EPS estimates by 21% and revenue by 18%, while raising dividends 33% and accelerating debt reduction. Valuation remains attractive with P/E of 9.87 and EV/EBITDA of 6.89, supported by $1.7B Q2 free cash flow and $8B buyback authorization.
Outlook remains positive with merger synergies tracking ahead of schedule and 2026 revenue guidance of $19.7B. Key risks include oil price volatility and integration execution from the Coterra merger. With 71% analyst buy ratings and $61.91 consensus target representing 36% upside, DVN offers compelling value for energy investors seeking growth and shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
